Patents by Inventor Günther Schütz

Günther Schütz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MEANS AND METHODS FOR TREATING OR PREVENTING BRAIN TUMORS BASED ON THE NUCLEAR RECEPTOR TAILLESS (TIX)
    Publication number: 20150168377
    Abstract: The present invention relates to the use of an inhibitor of tailless gene expression or tailless protein activity for the preparation of a pharmaceutical composition for treating or preventing the brain tumor in a subject. Preferably an inhibitor of tailless expression is a single or double stranded RNA. An inhibitor of tailless protein activity is preferably an antibody which specifically binds thereto. Finally, the invention includes methods for identifying anti-brain tumor drugs.
    Type: Application
    Filed: February 12, 2015
    Publication date: June 18, 2015
    Inventors: Hai-Kun LIU, Guenther Schuetz
  • Means and methods for treating or preventing brain tumors based on the nuclear receptor tailless (TIx)
    Patent number: 8992923
    Abstract: The present invention relates to the use of an inhibitor of tailless gene expression or tailless protein activity for the preparation of a pharmaceutical composition for treating or preventing the brain tumor in a subject. Preferably an inhibitor of tailless expression is a single or double stranded RNA. An inhibitor of tailless protein activity is preferably an antibody which specifically binds thereto. Finally, the invention includes methods for identifying anti-brain tumor drugs.
    Type: Grant
    Filed: February 22, 2013
    Date of Patent: March 31, 2015
    Assignee: DKFZ Deutsches Krebsforschungszentrum, Stiftung des Oeffentlichen Rechts
    Inventors: Hai-Kun Liu, Guenther Schuetz
  • Means and methods for treating or preventing brain tumors based on the nuclear receptor tailless (Tlx)
    Patent number: 8404657
    Abstract: The present invention relates to the use of an inhibitor of tailless gene expression or tailless protein activity for the preparation of a pharmaceutical composition for treating or preventing the brain tumor in a subject. Preferably an inhibitor of tailless expression is a single or double stranded RNA. An inhibitor of tailless protein activity is preferably an antibody which specifically binds thereto. Finally, the invention includes methods for identifying anti-brain tumor drugs.
    Type: Grant
    Filed: November 18, 2008
    Date of Patent: March 26, 2013
    Assignee: DKFZ Deutsches Krebsforschungszentrum, Stiftung des Oeffentlichen Rechts
    Inventors: Hai-Kun Liu, Günther Schütz
  • MEANS AND METHODS FOR TREATING OR PREVENTING BRAIN TUMORS BASED ON THE NUCLEAR RECEPTOR TAILLESS (TLX)
    Publication number: 20110038873
    Abstract: The present invention relates to the use of an inhibitor of tailless gene expression or tailless protein activity for the preparation of a pharmaceutical composition for treating or preventing the brain tumor in a subject. Preferably an inhibitor of tailless expression is a single or double stranded RNA. An inhibitor of tailless protein activity is preferably an antibody which specifically binds thereto. Finally, the invention includes methods for identifying anti-brain tumor drugs.
    Type: Application
    Filed: November 18, 2008
    Publication date: February 17, 2011
    Inventors: Hai-Kun Liu, Günther Schütz
  • Animal Model Based on Targeted Apoptosis for the Study of Genetic Diseases Such as Parkinson's Disease
    Publication number: 20100325742
    Abstract: Described is the use of a non-human transgenic animal, preferably a mouse, characterized in that it contains a modified version of the gene encoding TIF-IA (a) as an animal model for a disease, (b) for analyzing the function of selected stem cells or (c) for ablating malignant cells or microglia cells. Furthermore, methods for screening a therapeutic compound are described which comprise administering a candidate compound to said non-human transgenic animal (or a cell line derived from said non-human transgenic animal) and monitoring a therapeutic effect of said compound.
    Type: Application
    Filed: March 29, 2007
    Publication date: December 23, 2010
    Inventors: Ingrid Grummt, Rosanna Parlato, Günther Schütz, Xuejun Xuan, Grzegorz Kreiner, Claus Rieker